Source: Wisr
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Wisr (WZR) announces Chair John Nantes’ two-month leave of absence
  • Matthew Brown steps in as interim Chair to facilitate governance matters
  • John Nantes emphasises his support for the board’s actions and commitment to transparent governance
  • Wisr assures investors that Anthony Nantes’ termination does not involve financial irregularities or regulatory issues
  • Wisr shares are down 3.23 per cent, trading at 3 cents at 12:33 pm AEST

Wisr (WZR) has granted its Chair, John Nantes, a two-month leave of absence at his request.

During his temporary absence, Matthew Brown, the current Audit and Risk Management Committee Chair will serve as company interim Chair.

Mr Nantes made it clear that his decision to take leave is driven by the recent termination of Anthony Nantes, his family member, as CEO, and ongoing related matters.

“Although I was not involved in the deliberations which led to Anthony’s termination due to our familial relationship, I support the actions taken by my fellow board members,” he said. 

“In the interests of good and transparent governance and to allow for the efficient deliberation on and management of issues associated with Anthony’s tenure as CEO and his termination, I requested my board colleagues to grant a leave of absence.”

“The board appreciates John’s proactive approach in taking a leave of absence, to allow the board to address matters related to Anthony’s employment tenure and termination in an efficient and robust manner.” Mr Brown said.

Wisr assured investors that Anthony Nantes’ termination was not linked to any financial irregularity or regulatory contravention.

Wisr shares were down 3.23 per cent, trading at 3 cents at 12:33 pm AEST.

WZR by the numbers
More From The Market Online
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next
The words "Market Open" appear stacked atop one another next to ASX company iconography.

ASX Market Open: Ever-extending US loss streak to bleed into red Friday – unless Oz bucks trend again | Jan 3, 2024

The ASX 200 is expected to open 0.07% lower at 8,185 points, though after